OPKO Health, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- OPKO Health, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $88.00K, a 96.60% decline year-over-year.
- OPKO Health, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- OPKO Health, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- OPKO Health, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was -$208.00K.
- OPKO Health, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was -$208.00K.
- OPKO Health, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was -$272.00K.
- OPKO Health, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was -$774.00K, a 171.60% decline from fiscal 2021.
- OPKO Health, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $1.08M, a 42.99% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-03-31 | $88.00K 10-Q · filed 2025-05-01 | -$120.00K derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$208.00K 10-K · filed 2025-03-03 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.38M derived: sum of 4 quarters · filed 2025-03-03 |
| 2024-06-30 | -$208.00K 10-Q · filed 2024-08-07 | $2.41M derived: sum of 4 quarters · filed 2025-03-03 |
| 2024-03-31 | $2.59M 10-Q · filed 2024-05-07 | $2.32M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$272.00K 10-K · filed 2025-03-03 |
| 2023-09-30 | $28.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$301.00K 10-Q · filed 2024-08-07 | |
| 2022-12-31 | -$86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$774.00K 10-K · filed 2025-03-03 |
| 2022-09-30 | -$463.00K 10-Q · filed 2023-11-06 | -$485.00K derived: sum of 4 quarters · filed 2024-03-01 |
| 2022-06-30 | -$360.00K 10-Q · filed 2023-08-03 | $390.00K derived: sum of 4 quarters · filed 2024-03-01 |
| 2022-03-31 | $136.00K 10-Q · filed 2023-05-03 | $909.00K derived: sum of 4 quarters · filed 2024-03-01 |
| 2021-12-31 | $202.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $1.08M 10-K · filed 2024-03-01 |
| 2021-09-30 | $412.00K 10-Q · filed 2022-11-08 | $966.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $159.00K 10-Q · filed 2022-08-04 | $1.22M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $308.00K 10-Q · filed 2022-05-09 | |
| 2020-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $756.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | $669.00K 10-Q · filed 2021-10-28 | |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-06 | $0.00 derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$3.00K 10-K · filed 2022-03-01 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-05 | -$3.00K derived: sum of 4 quarters · filed 2021-02-18 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $853.00K derived: sum of 4 quarters · filed 2021-02-18 |
| 2019-03-31 | -$3.00K 10-Q · filed 2020-05-06 | $1.17M derived: sum of 4 quarters · filed 2021-02-18 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-18 | $1.17M 10-K · filed 2021-02-18 |
| 2018-09-30 | $856.00K 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $318.00K 10-Q · filed 2019-08-07 | |
| 2017-12-31 | $2.13M 10-K · filed 2020-03-02 | |
| 2016-12-31 | $8.61M 10-K · filed 2019-03-01 | |
| 2015-12-31 | $25.92M 8-K · filed 2019-01-29 | |
| 2014-12-31 | $12.93M 10-K · filed 2017-03-01 | |
| 2013-12-31 | $18.99M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $23.42M 10-K · filed 2016-02-29 |
| 2013-09-30 | $3.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | |
| 2013-06-30 | $23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | |
| 2013-03-31 | $905.00K 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $2.23M 10-K · filed 2015-02-27 | |
| 2011-12-31 | $984.00K 10-K · filed 2014-03-03 | |
| 2010-12-31 | $74.00K 10-K · filed 2013-03-18 | |
| 2009-12-31 | $694.00K 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |